Services

Antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibody removes core fucose from the sugar chain of the antibody, thereby enhancing the binding force of the antibody to the Fc receptor FcγIIIa (CD16a), increasing ADCC, and the antibody shows higher clinical efficacy effect. Creative Biolabs provides a series of ADCC/CDC enhanced antibody production and analysis services, bringing reliable support and accurate results to your project.

Therapeutic Fc Characterization Services Creative Biolabs offers a diverse portfolio of Fc functional characterization services. In particular, we offer cell-based functional assays for evaluating antibody effector functions and/or Fc engineering services for antibody function regulation. Click to Learn More

Therapeutic Antibody Glycan Characterization Creative Biolabs introduces a streamlined, end-to-end analytical platform for characterizing glycosylation profiles of therapeutic monoclonal antibodies (IgG1). In this platform, we use new column technology and high-resolution mass spectrometers to simplify sample preparation procedures. The analytes were then studied HILIC-UPLC/FLR/MS and the resulting data were analyzed to obtain glycosylation profile information in the Fc region to further characterize IgG1 heterogeneity. Click to Learn More

Stable Cell Line Service Creative Biolabs successfully established stable FUT8−/−-CHO cell lines for ADCC⁺ antibody production, Fucoanalog™ cell lines, and Glymax™ cell lines. In particular, our stable cell lines can be used for ADCC/CDC assay development, ADCC/CDC functional studies, and more. Click to Learn More

Therapeutic ADCC⁺/CDC⁺ Antibody Production and Analysis After your projects move to ADCC/CDC optimization, experts at Creative Biolabs show you how to accelerate the development, unleash your ADCC/CDC-enhanced antibody, and perform highly accurate and reliable ADCC/CDC analysis. ADCC⁺ Antibody Production CDC⁺ Antibody Production ADCC⁺ Antibody Analysis CDC⁺ Antibody Analysis Click to Learn More

ADCC/CDC⁺ Antibody Process Development Creative Biolabs provides upstream and early downstream development ADCC/CDC enhanced therapeutic antibody services to provide powerful, high-yield antibody products for your scientific research needs. Click to Learn More

cGMP ADCC/CDC⁺ Antibody Manufacturing Creative Biolabs offers an appropriate solution for ADCC/CDC-enhanced cGMP manufacturing needs. Our proprietary CHO stable cell line platform enables us to provide you with high yields, traceable, and consistent GMP protein in a variety of batches. Every step of our manufacturing process meets global standard quality control guidelines. Click to Learn More

Therapeutic Antibody Engineering Services Creative Biolabs is committed to providing comprehensive therapeutic antibody engineering services for boosting customers' antibody research into the market. Leveraged by our cutting-edge technology platform, Creative Biolabs focuses on antibody modification to optimize the therapeutic antibody engineering process and achieve the specific product profile and endpoints you are aiming for in your antibody therapy. Click to Learn More

Benefits of Our Services

• Extensive experience.
• A wide variety of cells.
• Positive antibody references were provided.
• Methodologically validated cell line analysis platform.
• Meet new drug submission compliance documents.
• Multiple validated and audit-available microplate readers.

Through our expertise in antibody manufacturing and state-of-the-art technology and instrumentation, Creative Biolabs is committed to providing customers with the best ADCC/CDC antibody engineering services and ensuring that every step of the process meets your requirements. If you are interested, please feel free to contact us.

References

1. Saxena, Abhishek, and Donghui Wu. "Advances in therapeutic Fc engineering–modulation of IgG-associated effector functions and serum half-life." Frontiers in immunology 7 (2016): 580.
2. Liu, Sheng, et al. "Comprehensive N-glycan profiling of cetuximab biosimilar candidate by NP-HPLC and MALDI-MS." PloS one 12.1 (2017): e0170013.
3. Szczesny, Roman J., et al. "Versatile approach for functional analysis of human proteins and efficient stable cell line generation using FLP-mediated recombination system." PloS one 13.3 (2018): e0194887.
4. Saeed, Abdullah FUH, et al. "Antibody engineering for pursuing a healthier future." Frontiers in microbiology (2017): 495.
5. Verhoeven, Dorit, et al. "Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy." Clinical Immunology 190 (2018): 22-31.